# Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

> **NCT03073200** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 201 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Ixekizumab
- **DRUG:** Placebo
- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT03073200
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-28
- **Primary completion:** 2019-02-07
- **Final completion:** 2021-03-23
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2021-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03073200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03073200, "Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03073200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*